Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 31, 2018 - Issue 3
Submit an article Journal homepage
41
Views
4
CrossRef citations to date
0
Altmetric
Case Studies

Dramatic response to cyclin D–dependent kinase 4/6 inhibitor in refractory poorly differentiated neuroendocrine carcinoma of the breast

Allison ShanksTexas A&M College of Medicine, Temple, TexasCorrespondence[email protected]
, BS,
Julia ChoiTexas A&M College of Medicine, Temple, Texas;Department of Hematology and Oncology, Baylor Scott and White, Temple, Texas
, MD &
Vinit KarurTexas A&M College of Medicine, Temple, Texas;Department of Hematology and Oncology, Baylor Scott and White, Temple, Texas
, MD, PhD
Pages 352-354 | Received 31 Jan 2018, Accepted 22 Mar 2018, Published online: 09 May 2018

  • Wang J, Wei B, Albarracin CT, Hu J, Abraham SC, Wu Y. Invasive neuroendocrine carcinoma of the breast: a population-based study from the Surveillance, Epidemiology and End Results (SEER) database. BMC Cancer. 2014;14:147–157. doi:10.1186/1471-2407-14-147. PMID:24589259.
  • Wei B, Ding T, Xing Y, et al. Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma. Cancer. 2010;116:4463–4473. doi:10.1002/cncr.25352. PMID:20572042.
  • Zhang Y, Chen Z, Bao Y, et al. Invasive neuroendocrine carcinoma of the breast: a prognostic research of 107 Chinese patients. Neoplasma. 2013;60:215–222. doi:10.4149/neo_2013_029. PMID:23259792.
  • Tian Z, Wei B, Tang F, et al. Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol. 2011;42:1169–1177. doi:10.1016/j.humpath.2010.11.014. PMID:21334720.
  • Yavas G, Karabagli P, Araz M, Yavas C, Ata O. HER-2 positive primary solid neuroendocrine carcinoma of the breast: a case report and review of the literature. Breast Cancer. 2015;22:432–436. doi:10.1007/s12282-012-0382-x. PMID:22711316.
  • Lee DH, Park AY, Seo BK, Kim YS, Lee KY, Cha SH. Primary neuroendocrine carcinoma of the breast with clinical features of inflammatory breast carcinoma: a case report and literature review. J Breast Cancer. 2015;18:404–408. doi:10.4048/jbc.2015.18.4.404. PMID:26770249.
  • Tato-Varela S, Albalat-Fernández R, Pabón-Fernández S, Zarco ER, Calle-Marcos ML. Primary neuroendocrine tumour of the breast: a case report and review of the literature. Ecancermedicalscience. 2015;9:607. doi:10.3332/ecancer.2015.607. PMID:26798407.
  • Shin SJ, DeLellis RA, Ying L, Rosen PP. Small cell carcinoma of the breast: a clinicopathologic and immunohistochemical study of nine patients. Am J Surg Pathol. 2000;24:1231–1238. doi:10.1097/00000478-200009000-00006. PMID:10976697.
  • Jochems L, Tjalma WA. Primary small cell neuroendocrine tumour of the breast. Eur J Obstet Gynecol Reprod Biol. 2004;115:231–233. doi:10.1016/j.ejogrb.2003.12.013. PMID:15262362.
  • Savelli G, Zaniboni A, Bertagna F, et al. Peptide receptor radionuclide therapy (PRRT) in a patient affected by metastatic breast cancer with neuroendocrine differentiation. Breast Care (Basel). 2012;7:408–410. doi:10.1159/000343612. PMID:24647781.
  • Ang D, Ballard M, Beadling C, et al. Novel mutations in neuroendocrine carcinoma of the breast: possible therapeutic targets. Appl Immunohistochem Mol Morphol. 2015;23:97–103. doi:10.1097/PDM.0b013e3182a40fd1. PMID:25679062.
  • Marchiò C, Geyer FC, Ng CK, et al. The genetic landscape of breast carcinomas with neuroendocrine differentiation. J Pathol. 2017;241:405–419. doi:10.1002/path.4837. PMID:27925203.
  • Juric D, Ismail-Khan R, Campone M, et al. Phase Ib/II study of ribociclib and alpelisib and letrozole in ER+, HER2− breast cancer: safety, preliminary efficacy and molecular analysis [abstract]. Cancer Res. 2016;76. doi:10.1158/1538-7445.SABCS15-P3-14-01.
  • Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–166. doi:10.1038/nrc2602. PMID:19238148.
  • Rocca A, Schirone A, Maltoni R, et al. Progress with palbociclib in breast cancer: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017;9:83–105. doi:10.1177/1758834016677961. PMID:28203301.
  • Finn F, Jiang Y, Rugo H, et al. Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER+/HER2− advanced breast cancer (ABC). Ann Oncol. 2016;27(Suppl 6):1–36. https://doi.org/10.1093/annonc/mdw435.05.
  • Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45:1446–1451. doi:10.1038/ng.2823. PMID:24185510.
  • Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45:1439–1445. doi:10.1038/ng.2822. PMID:24185512.
  • Mamo A, Cavallone L, Tuzmen S, et al. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene. 2012;31:2090–2100. doi:10.1038/onc.2011.386. PMID:21892209.
  • Bitler BG, Aird KM, Garipov A, et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med. 2015;21:231–238. doi:10.1038/nm.3799. PMID:25686104.
  • Samartzis EP, Gutsche K, Dedes KJ, Fink D, Stucki M, Imesch P. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget. 2014;5:5295–5303. doi:10.18632/oncotarget.2092. PMID:24979463.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.